Home > Insider Trading > Filing (0001104659-16-130152)

Filing Details

Accession Number:: 0001104659-16-130152
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-06-29 16:49:20
Reporting Period:: 2016-06-27

Filing Date:: 2016-06-29
Accepted Time:: 2016-06-29 16:49:20
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1453687	Selecta Biosciences Inc	SELB	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1282930	L Carl Gordon	C/O Selecta Biosciences, Inc. 480 Arsenal Street, Building One Watertown MA 02472		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-06-27	11,111	$0.00	12,193	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2016-06-27	1,166,884	$0.00	1,280,604	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2016-06-27	5,189	$14.00	17,382	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2016-06-27	544,811	$14.00	1,825,415	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series C Convertible Preferred Stock	Disposition	2016-06-27	3,628	$0.00	3,628	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2016-06-27	380,986	$0.00	380,986	$0.00
Common Stock	Series D Convertible Preferred Stock	Disposition	2016-06-27	739	$0.00	739	$0.00
Common Stock	Series D Convertible Preferred Stock	Disposition	2016-06-27	77,697	$0.00	77,697	$0.00
Common Stock	Series E Convertible Preferred Stock	Disposition	2016-06-27	4,351	$0.00	6,744	$0.00
Common Stock	Series E Convertible Preferred Stock	Disposition	2016-06-27	456,870	$0.00	708,201	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

The reportable securities are owned directly by OrbiMed Associates III, LP ("Associates III"). OrbiMed Advisors LLC ("Advisors") is the general partner of Associates III. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of and owner of a controlling interest in Advisors. By virtue of such relationships, Advisors and Isaly may be deemed to have voting and investment power over the securities held by Associates III and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a member of Advisors.
The reportable securities are owned directly by OrbiMed Private Investments III, LP ("OPI III"). OrbiMed Capital GP III LLC ("GP III") is the general partner of OPI III, and Advisors is the managing member of GP III. Isaly is the managing member of and owner of a controlling interest in Advisors. By virtue of such relationships, GP III, Advisors and Isaly may be deemed to have voting and investment power over the securities held by OPI III and as a result may be deemed to have beneficial ownership over such securities.
The preferred stock is convertible at any time, at the holder's election and has no expiration date. The preferred stock automatically converted into common stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering.
The Series E Convertible Preferred Stock is convertible at any time, at the holder's election and has no expiration date. The Series E Convertible Preferred Stock automatically converted into common stock on an approximately 1-for-1.550115 basis upon the closing of the Issuer's initial public offering.
Each of GP III, Advisors, Islay and the reporting person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of GP III, Advisors, Islay, or the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.